Grant ID DP230064
Awarded On May 17, 2023
Title IND-Enabling Studies of ONP-001: A Nano-Codelivery Formulation with Two Drugs of Distinct Mechanisms of Action for Treating Pancreatic Ductal Adenocarcinoma
Program Product Development Research
Award Mechanism Seed Awards for Product Development Research
Institution/Organization OmniNano Pharmaceuticals LLC
Principal Investigator/Program Director Guorong Ma
Cancer Sites Pancreas
Contracted Amount $2,711,437
Lay Summary

OmniNano Pharmaceuticals is a pharmaceutical technology startup located in Missouri City, TX. Omninano is developing nano-codelivery formulations with two drugs of distinct mechanisms of action for treating solid tumors. The foundational work has been done at the University of Texas MD Anderson Cancer Center and the University of Houston. Our lead product, ONP-001 is designed to treat pancreatic cancer. In 2022, 62,210 new pancreatic cases will be diagnosed in the US, with 49,830 deaths and a 5-year survival rate of only 11.5%. Extant drug therapies have very limited efficacy, with more than half of all pancreatic cancer patients dying within 12 months of diagnosis. Furthermore, current trea...

Read More